Roche has agreed to out-license certain rights to its invesitgational atropic dermatitis drug lebrikizumab to Demira in a deal that could be worth more than $1.4 billion.

Dermira will obtain exclusive, worldwide rights to develop and commercialize lebrikizumab, a monoclonal antibody targeting interleukin 13 (IL-13), for atopic dermatitis and all other indications – except for interstitial lung diseases, such as idiopathic pulmonary fibrosis, the rights for which will remain with Roche.

http://www.pharmatimes.com/news/roche_out-licneses_lebrikizumab_to_dermira_1200863

About news

We take care of publishing the latest investment news and highlights for Feedback

Leave a Reply

Your email address will not be published. Required fields are marked *